Subconjunctival Bevacizumab as an Adjunct to Trabeculectomy in Eyes with Refractory Glaucoma: A Case Series.
- Author:
Jin Young CHOI
1
;
Jaewan CHOI
;
Yeon Deok KIM
Author Information
- Publication Type:Case Report
- Keywords: Angiogenesis Inhibitors; Glaucoma; Monoclonal antibodies; Trabeculectomy; Vascular endothelial growth factors
- MeSH: Adult; Aged; Angiogenesis Inhibitors/*administration & dosage; Antibodies, Monoclonal/*administration & dosage; Conjunctiva; Female; Glaucoma/*drug therapy/etiology/*surgery; Glaucoma, Neovascular/drug therapy/surgery; Humans; Injections, Intraocular; Male; Middle Aged; Prospective Studies; Trabeculectomy/*methods; Uveitis/complications; Vascular Endothelial Growth Factor A/*antagonists & inhibitors; Vitrectomy/adverse effects
- From:Korean Journal of Ophthalmology 2010;24(1):47-52
- CountryRepublic of Korea
- Language:English
- Abstract: This prospective observational case series study included 6 eyes of 6 consecutive glaucomatous patients. Each patient underwent trabeculectomy with mitomycin C, and received a 1.25 mg of subconjunctival bevacizumab injection at completion of the trabeculectomy. Study eyes included two with neovascular glaucoma, three with uveitic glaucoma, and one with secondary glaucoma following vitrectomy. All eyes had undergone failed glaucoma laser/surgical treatment or an intraocular surgical procedure. Intraocular pressure (IOP) at the following postoperative visits: preoperative, 1 week, 1 month, 2 months, 3 months, and 6 months, was measured. We also evaluated postoperative bleb findings and complications. IOP measured at each visit was 37.5+/-14.4 mmHg, 6.2+/-3.4 mmHg, 8.3+/-7.2 mmHg, 12.0+/-4.4 mmHg, 10.8+/-3.1 mmHg, and 12.2+/-3.3 mmHg, respectively, for each visit. All eyes had functioning blebs with normal IOP at postoperative 6 months with no additional IOP-lowering medication.
